Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 274 | 1 | 288 | +15 |
| Shares | 83.9M | 13.2K | 84.4M | +550.7K (+0.7%) |
| Value | $4.55B | $782.5K | $5.34B | +$797.5M (+17.5%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (51)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (36)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (1)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Stonnington Group, LLC | 13,200 | $782.5K |